Text Size

Cholesterol Goal Attainment Rate and Its Associated Factors Among Dyslipidemic Patients on Lipid-lowering Drug Therapy in Korea (CRESENDO)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
AstraZeneca
ClinicalTrials.gov Identifier:
NCT01372956
First received: June 7, 2011
Last updated: December 21, 2011
Last verified: December 2011
History of Changes
  Purpose

This is a multi-centre, cross-sectional, chart review study to investigate cholesterol goal attainment rates defined by modified NCEP-ATP III guidelines and define its possible determinants among Korean dyslipidemic patients


Condition
Dyslipidemia

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Retrospective
Official Title: Cholesterol Goal Attainment Rate and Its Associated Factors Among Dyslipidemic Patients on Lipid-lowering Drug Therapy in Korea (CRESCENDO)

Resource links provided by NLM:

MedlinePlus related topics: Cholesterol
U.S. FDA Resources

Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • Cholesterol goal attainment rate according to NCEP-ATP III guideline [ Time Frame: Once, at enrollment ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Factors for cholesterol goal achievement: Age, Family history, smoking history, waist circumstance, etc. [ Time Frame: Once, at enrollment ] [ Designated as safety issue: No ]
  • Cholesterol goal attainment rate related to CHD or disease history [ Time Frame: Once, at enrollment ] [ Designated as safety issue: No ]

Enrollment: 4950
Study Start Date: August 2011
Study Completion Date: October 2011
Primary Completion Date: October 2011 (Final data collection date for primary outcome measure)
Groups/Cohorts
Dyslipidemia

Detailed Description:

MC MD

  Eligibility

Ages Eligible for Study:   19 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

Primary Care

Criteria

Inclusion Criteria:

  • Patient who has a dyslipidemia with a lipid profile result within 3 months
  • Patient who has a dyslipidemia without change of lipid lowering drug dosage during 3 months after lipid profile test.

Exclusion Criteria:

  • Patient who involved in this study previously.
  • Patient who participated in other clinical study with study drug within 90 days.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01372956

Locations
Korea, Republic of
Research Site
Cheongju, Chungcheongbuk-do, Korea, Republic of
Research Site
Cheonan, Chungcheongnam-do, Korea, Republic of
Research Site
Tae, Chungcheongnam-do, Korea, Republic of
Research Site
Anyang, Gyeonggi-do, Korea, Republic of
Research Site
Bucheon, Gyeonggi-do, Korea, Republic of
Research Site
Bundang, Gyeonggi-do, Korea, Republic of
Research Site
Goyang, Gyeonggi-do, Korea, Republic of
Research Site
Guri, Gyeonggi-do, Korea, Republic of
Research Site
Uijeongbu, Gyeonggi-do, Korea, Republic of
Research Site
Gwangju, Jeollabuk-do, Korea, Republic of
Research Site
Iksan, Jeollabuk-do, Korea, Republic of
Research Site
Chuncheon, Kangwon-do, Korea, Republic of
Research Site
Daegu, Kyeongsangbuk-do, Korea, Republic of
Research Site
Deagu, Kyeongsangbuk-do, Korea, Republic of
Research Site
Busan, Kyeongsangnam-do, Korea, Republic of
Research Site
Changwon, Kyeongsangnam-do, Korea, Republic of
Research Site
Busan, Korea, Republic of
Research Site
Gwangju, Korea, Republic of
Research Site
Incheon, Korea, Republic of
Research Site
Seoul, Korea, Republic of
Sponsors and Collaborators
AstraZeneca
Investigators
Principal Investigator: Jeong Ui Park Samsung Medical Center
Principal Investigator: Jong sung Kim Seoul National University Hospital
Principal Investigator: Sung woo Park Kangbuk Samsung Medical center
  More Information

No publications provided

Responsible Party: AstraZeneca
ClinicalTrials.gov Identifier: NCT01372956     History of Changes
Other Study ID Numbers: NIS-CKR-XXX-2011/1
Study First Received: June 7, 2011
Last Updated: December 21, 2011
Health Authority: South Korea: Korea Food and Drug Administration (KFDA)

Keywords provided by AstraZeneca:
LDL-C, cholesterol, risk factor

Additional relevant MeSH terms:
Dyslipidemias
Lipid Metabolism Disorders
Metabolic Diseases
Hypolipidemic Agents
Antimetabolites
 Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Lipid Regulating Agents
Therapeutic Uses

ClinicalTrials.gov processed this record on May 21, 2013